(Body Protection Compound-157) is a synthetic pentadecapeptide investigated mainly in cells and animal models for effects on tissue repair biology, angiogenesis, and gastrointestinal integrity
demonstrated that fusion of GHBP to a GHR antagonist protein similar to B2036 significantly reduced IGF1 by 14% after a single subcutaneous injection in rabbits and may be useful for treating acromegaly
Short-term studies havent found acute safety issues, but because there are no long-term human studies, its safety over time is unknown
You really might just need to give your body some time to recover from your hangover
Mervyn Vergouwen: Bayer BV (investigator-initiated research, paid to instution) Poster Session II - INTRACRANIAL HEMORRHAGE 02.00 - INTRACRANIAL HEMORRHAGE - 02.01 - INTRACEREBRAL HAEMORRHAGE P770 - ESOC25-2045 TRACKING EARLY-DISEASE CHANGES IN DUTCH-TYPE HEREDITARY CAA: PRELIMINARY BASELINE RESULTS OF THE TRACK D-CAA STUDY Rosemarie van Dort 1 , Reinier van der Zwet 1 , Manon Schipper 1 , Neal Parikh 2 , Hamid Sohrabi 3 , Ralph Martins 4 , Steven Greenberg 5 , Marianne van Walderveen 1 , Matthias van Osch 1 , Marieke Wermer 6 1 Leiden University Medical Center, Leiden, Netherlands, 2 Alnylam Pharmaceuticals, Massachusetts, United States, 3 Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Perth, Australia, 4 Alzheimers Research Australia, & The Centre of Excellence for Alzheimers Disease Research and Care, Edith Cowan University, Perth, Australia, 5 Massachusetts General Hospital, Boston, United States, 6 University Medical Center Groningen, Groningen, Netherlands Background and Aims: This study aimed to investigate early disease biomarkers and natural history in D-CAA mutation-carriers and characterize disease progression over time
The price also depends on the type of peptide prescribed, the dosage, how often it is taken, and whether it comes as injections, capsules, or creams
